In theory, the vaccine is also effective against South African and Brazilian strains. “EpiVacCorona” of Novosibirsk “Vector” is effective against the British strain of coronavirus
Experts from “Vector” announced the effectiveness of “EpiVacCorona” against the British strain of coronavirus.
“In practice, we have confirmed the effectiveness of the EpiVacCorona vaccine not only against the classic reference variants of the new coronavirus, but also against the British strain. This virus was obtained in the Russian Federation at the end of December last year, we conducted an in-depth study of it, and now the sera of people vaccinated with EpiVacCorona successfully neutralize the British strain with the same efficiency as the classical reference variants, ”said the general director of the scientific center “Vector” Rinat Maksyutov in an interview with the federal channel “Russia 24”.
As for other variants of the new coronavirus, such as the South African and Brazilian strains, a theoretical analysis of their sequence suggests that the EpiVacCorona vaccine will be equally effective against them.
– Peptides are selected as the most conservative, unchanging regions of viral proteins, and no substitutions occur in these sequences in these new variants of strains. In practice, as soon as we receive these viral isolates, we will conduct this study, – explained Rinat Maksyutov.
Experts of “Vector” told about the effectiveness of the vaccine “EpiVacCorona” in the elderly
Elderly participants in clinical trials tolerated the vaccine mostly easily
At the Novosibirsk Center for Virology and Biotechnology “Vector” they talked about how effective the EpiVacCorona coronavirus vaccine is for the elderly.
Clinical trials of the vaccine among people over 60 were completed at the center in early February. Then the acting deputy general director for scientific and methodological work and international cooperation of “Vector” Tatyana Nepomnyashchikh noted that the participants (there were 150 of them) tolerated vaccination mostly easily.
Rinat Maksyutov, general director of the Vector Research Center, in an interview with the Rossiya 24 federal channel, spoke about the effectiveness of the vaccine:
– After vaccination, 94% of volunteers over 60 years of age developed immunity. But given this age, we believe that this is a high percentage. In the near future, it is planned to amend the instructions for using the vaccine, and I am sure that by the end of February the vaccine will be available to volunteers and residents of the Russian Federation over 60 years of age within the framework of civil circulation.
Taking into account the age of the volunteers, experts called this percentage of people with immunity high.
Earlier it became known that “Vector” plans to release more than a million doses of “EpiVacCorona” per month together with its subsidiary “Vector-BiAlgam”.